IGF-I Injections Explored for Boosting Collagen in Ehlers-Danlos Syndrome

Individuals with Ehlers-Danlos Syndrome (EDS), particularly the Classic type, often experience significant issues with connective tissue integrity due to defects in collagen production. This leads to symptoms like joint hypermobility, skin hyperextensibility, and tissue fragility. While the underlying genetic causes are known, effective treatments to strengthen the compromised connective tissue remain limited. This study aimed to investigate if insulin-like growth factor-I (IGF-I) could stimulate collagen synthesis in these patients, potentially offering a novel therapeutic approach.

While specific quantitative results detailing the extent of collagen synthesis stimulation were not provided in this summary, the study's primary objective was to measure this response in muscle connective tissue and skin. The investigators hypothesized that connective tissue in Ehlers-Danlos patients would exhibit greater compliance and lower collagen content compared to healthy controls. The core aim was to determine if IGF-I could counteract this deficiency. The study enrolled 15 actual participants, indicating a focused investigation into this mechanism. The central hypothesis driving this research was that IGF-I could effectively stimulate collagen synthesis, thereby potentially improving the compromised connective tissue in Ehlers-Danlos Syndrome patients.